Author/Authors :
William R. Lewis MD FACC، نويسنده , , Ezra A. Amsterdam، نويسنده ,
Keywords :
Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIa/IIIb blockade trial , percutaneous transluminal coronary angioplasty , Abciximab before Direct angioplasty and stenting in Myocardial Infarction Regarding Acute and Long-term follow-up , Evaluation of Platelet Inhibition in STENTing trial , peripheral vascular disease , ADMIRAL , EPISTENT , PVD , CABG , ERASER , Rapport , coronary artery bypass grafting , Evaluation of ReoPro And Stenting to Eliminate Restenosis , ReoPro And Primary PTCA Organization and Randomized Trial , Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications , glycoprotein IIb/IIIa , capture , HR , C7E3 AntiPlatelet Therapy in Unstable REfractory angina trial , Hazard ratio , CHF , ISAR-2 , Congestive heart failure , Intracoronary Stenting and Antithrombotic Regimen-2 trial , CI , MI , Confidence interval , myocardial infarction , Evaluation of 7E3 in Preventing Ischemic Complications trial , Percutaneous coronary intervention , EPIC , PCI , EPILOG , PTCA , CADILLAC , GP IIb/IIIa
